AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

PHASE3TerminatedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

warfarin

Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.

DRUG

placebo

Oral placebo (1mg or 2.5mg)

Trial Locations (22)

10021

Weill Medical College of Cornell University, New York

14620

Highland Hospital - University of Rochester Medical Center, Rochester

19104

University of Pennsylvania Health System, Philadelphia

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

33136

University of Miami Miller School of Medicine, Miami

35294

University of Alabama - Birmingham, Birmingham

37232

Vanderbilt University, Nashville

40425

University of Louisville, Louisville

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

63017

St. Luke's Hospital, Chesterfield

70118

Tulane University, New Orleans

75390

University of Texas Southwestern Medical Center, Dallas

80206

National Jewish Medical and Research Center, Denver

84108

University of Utah Health Research Center, Salt Lake City

90095

University of California - Los Angeles, Los Angeles

94110

University of California - San Francisco, San Francisco

98165

University of Washington, Seattle

06520-8057

Yale University School of Medicine, New Haven

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Duke Clinical Research Institute

OTHER

lead

Duke University

OTHER